In non-GIST soft tissue sarcomas that harbor PDGFR gene mutation, as well as in 10% of GISTs that exhibit this specific mutation, the PDGFR–targeting drug olaratumab has been approved for treatment [4]. This evidence concerns the gene PDGFRB and soft tissue sarcoma.